- Longitudinal studies: The VapeScan Study is cross-sectional. Long-term follow-up studies tracking vapers over 10-20 years are needed to determine whether the blood pressure increase leads to clinical cardiovascular disease.
- Product-specific research: The study did not distinguish between FDA-authorized and unauthorized products, or between device types (pod systems, disposables, mods). Future research should examine whether specific device types or nicotine concentrations carry different cardiovascular risks.
- Cooling ingredient studies: The June 2026 study on synthetic cooling agents (WS-23) and arrhythmias suggests that specific vape ingredients may have independent cardiovascular effects. Expect more research on flavor compounds and heart health.
- FDA regulatory response: The FDA may consider cardiovascular risk data in future PMTA decisions. The VapeScan findings could influence the agency's approach to authorizing new products, particularly flavored products that appeal to young adults.
- Nicotine reduction: If nicotine is the primary driver of the blood pressure effect (as the sympathetic nervous system mechanism suggests), FDA-mandated nicotine reduction in vaping products could reduce cardiovascular risk.
What to watch: The VapeScan Study is the first major study to directly measure cardiovascular risk markers in young adult vapers. Expect follow-up studies examining specific device types, nicotine concentrations, and flavor compounds. The American Heart Association has already called for more research, and the FDA will likely consider these findings in future regulatory decisions. If you vape, monitor your blood pressure — it is the most actionable finding from this study.
